Sien Zhang

Dr. Sien Zhang


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2023 in Acta Biomaterialia
Verified
Journal Article
Closed access
TWTao Wang
Tao Wang
QHQiting Huang
Qiting Huang
ZRZilong Rao
Zilong Rao
FLFan Liu
Fan Liu
XSXinyun Su
Xinyun Su
SZSien Zhang
Sien Zhang

14 June 2023 in Clinical Oral Investigations
Verified
Journal Article
Open access
PDF file
JMJingxin Ma
Jingxin Ma
XZXuefan Zhai
Xuefan Zhai
MHMin Huang
Min Huang
PLPeiyao Li
Peiyao Li
YLYujie Liang
Yujie Liang
SZSien Zhang
Sien Zhang
Objectives: Oncologic risk is a serious concern of submental artery island flaps. Here, we introduce the contralateral-based submental artery island flap (C-SAIF) and demonstrate its feasibility and long-term oncological safety in reconstructing oral cancer–related defects. Methods: An anatomical study was performed concentrating on the pedicle length in seven cadavers. Then, a retrospective study was carried out on C-SAIF patients operated on by a single team. The standard surgical technique of C-SAIF was conducted. Outcomes including operative time, length of hospital stay, volume of intraoperative blood loss, and scores of the Multidisciplinary Salivary Gland Society (MSGS) questionnaire were compared with a similar cohort reconstructed with anterolateral thigh free flap (ALTF). In addition, oncological outcomes were evaluated by the 5-year cumulative survival rate between C-SAIF and ALTF patients. Results: The pedicle length of C-SAIF was sufficient for the flap to be extended to the contralateral oral cavity. Fifty-two patients were included in the retrospective study, and nineteen of them underwent reconstruction with C-SAIF. The operative time of C-SAIF was shorter (p = 0.003), and the intraoperative blood loss was less (p = 0.004) than that of ALTF. There was no difference in MSGS scores. The results of survival analysis revealed comparable survival curves for the two groups in terms of overall survival, disease-specific survival, and disease-free survival. Conclusion: C-SAIF is a feasible and reliable flap for reconstructing oral cancer–related defects. Moreover, it is an effective island flap to preserve the perforator and pedicle without compromising oncological safety.

4 June 2024 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
MHMin Huang
Min Huang
PLPeiyao Li
Peiyao Li
LYLe Yang
Le Yang
YXYudong Xiao
Yudong Xiao
LZLingchan Zeng
Lingchan Zeng
SZSien Zhang
Sien Zhang
Objectives: To avoid the oncologic risks of ipsilateral regional flaps, this study aimed to explore the feasibility and clinical outcomes of the contralateral-based facial artery myomucosal island flap (C-FAMMIF) for oral T2–T3 oncologic defects reconstruction.Methods: A study of flap anatomy was conducted on 7 cadaver samples and a cohort of 24 patients who received C-FAMMIF reconstruction after malignancy resection were retrospectively researched. A balanced anterolateral thigh flap (ALT) group of 47 patients was extracted as control group using propensity score matching method. Progression-free survival (PFS), functional outcomes, and donor site complications were assessed.Results: Consistent blood supply and drainage through facial artery and vein with median maximum pedicle length of 106 mm supported contralateral reconstruction. The superficial vein drainage pattern indicated safer flap harvest at contralateral neck under circumstances of ipsilateral neck dissections. The pedicle and marginal facial nerve formed three anatomical patterns. The surgical management of each was described. Patients with ipsilateral pN+ neck accounted for 41.7% and 40.4% in the C-FAMMIF and ALT group, respectively. The 2-year PFS rate between the C-FAMMIF and ALT groups was not significantly different (88.2% in C-FAMMIF group and 84.6% in ALT group, respectively, p = 0.6358). Promising recoveries were observed for swallowing function and tactile sensation. The donor sites healed upon primary closure without trismus or permanent facial palsy.Conclusion: Our findings suggested that C-FAMMIF is feasible and safe for T2-T3 oral oncologic defect reconstruction in patients with ipsilateral cN+ neck.

30 March 2024 in Journal of Stomatology Oral and Maxillofacial Surgery
Verified
Journal Article
Open access
PLPeiyao Li
Peiyao Li
FLFan Liu
Fan Liu
ZLZhi Lin
Zhi Lin
MHMin Huang
Min Huang
JMJingxin Ma
Jingxin Ma
SZSien Zhang
Sien Zhang
This study aimed to assess the functional and esthetic outcomes of a chimeric innervated buccinator myomucosal-submental island flap (BMM-SIF) for large composite lower lip reconstruction. This retrospective study included five patients who underwent lower lip tumor resection and BMM-SIF reconstruction at the Hospital of Stomatology, Sun Yat-sen University, between August 2021 and February 2023. Lip function was evaluated using water leakage, cheek puffing tests, and superficial electromyography. Lip appearance was observed using photographs and evaluated through subjective interviews. Donor-site conditions, including facial symmetry and mouth opening, were monitored. All the BMM-SIFs survived. Drooling was the main complication observed shortly after surgery. The water leakage test showed complete oral competence for liquid holding in the 7th month; however, moderate air leakage was present in two patients. Electromyography revealed myoelectric signals from the innervated buccinator at the recipient site. Facial expression and food intake were typically managed. The shape and projection of the vermilion were harmonious and satisfactory for each patient. Neither microstomia nor mouth opening limitation was observed, with an average inter-incisor distance of 37.25±4.4 mm. Chimeric motor-innervated BMM-SIF effectively reconstructed large full-thickness lower-lip defects with satisfactory functional and esthetic outcomes.

30 January 2026 in Clinical and Translational Medicine
Verified
Journal Article
Open access
ZWZhuokai Wu
Zhuokai Wu
CCChixing Cheng
Chixing Cheng
ZLZhaoxin Li
Zhaoxin Li
MRMinyi Ren
Minyi Ren
HCHongxi Cao
Hongxi Cao
YWYixi Wang
Yixi Wang
Background: Lymph node (LN) metastasis is a well‐established independent prognostic factor in head and neck squamous cell carcinoma (HNSCC). Formation of suppressive tumour immune microenvironment (TIME) is a major contributor to tumour immune evasion and metastasis. However, the TIME landscape underlying LN‐metastatic HNSCC remains poorly elucidated. Methods: A total of 688 866 single‐cell transcriptomes across 212 HNSCC samples were integrated. Comprehensive bioinformatic analyses on single‐cell RNA sequencing and microarray datasets revealed a TREM2 + tumour‐associated macrophage (TAM) cluster associated with LN metastasis. The functional role of TREM2 + TAMs was investigated through multiplex immunohistochemistry (mIHC) staining in clinical HNSCC cohort and in vitro co‐culture experiments. Furthermore, machine learning algorithms were employed to construct a prognostic model for HNSCC. Results: Integrative single‐cell analysis revealed the immunosuppressive TIME of LN‐metastatic HNSCC, characterised by high infiltration of exhausted CD8 + T cells (CD8 + Tex). We identified a specific TREM2 + TAM cluster that was strongly associated with CD8 + Tex infiltration and LN metastasis. In vitro experiment confirmed that TREM2 + TAMs promoted CD8 + T cell exhaustion. Mechanistically, TREM2 + TAMs exhibited a terminally differentiated phenotype driven by ETV5, and secreted SPP1 to interact with CD44 on CD8 + T cells, thus upregulating BHLHE40 to promote CD8 + Tex formation. Clinically, a prognostic model based on TREM2 + TAM signature genes was trained to independently predict HNSCC outcomes. Conclusions: This study delineates the mechanism that TREM2 + TAMs promote LN metastasis in HNSCC by facilitating CD8 + T cells exhaustion via SPP1–CD44–BHLHE40 axis, proposing TREM2 + TAMs as potential therapeutic target for HNSCC.

27 February 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
SSShuyuan Song
Shuyuan Song
ZLZhentao Lao
Zhentao Lao
RYRuotong Yu
Ruotong Yu
SYShan Yu
Shan Yu
PLPeiyao Li
Peiyao Li
SZSien Zhang
Sien Zhang
Objective: Although immune checkpoint inhibitors (ICIs) have improved survival in head and neck squamous cell carcinoma (HNSCC), associated adverse events, such as sialadenitis, remain poorly characterized. This study aimed to define the clinicopathological features, establish the causal pathogenic mechanism, and validate a therapeutic target for ICI-associated sialadenitis. Methods: This study integrated three complementary approaches. First, a prospective cohort of 25 HNSCC patients underwent functional assessment of salivary and lacrimal glands before and after ICI therapy. Second, salivary gland tissues from separate cohorts of ICI-treated (n=30) and untreated control (n=30) patients were subjected to comprehensive analysis, including histology, multi-platform immunophenotyping (immunohistochemistry, multiplex immunofluorescence, flow cytometry), and cytokine quantification at both transcript and protein levels. Finally, a preclinical mouse model was established to confirm causality and validate the therapeutic efficacy of IL-17A blockade. Results: Following ICI treatment, patients showed significantly reduced salivary and lacrimal secretion ( P < 0.05). Histopathological analysis revealed extensive lymphocytic infiltration, marked periductal fibrosis, and substantial loss of acinar structures. The immune infiltrate was dominated by CD4 + T cells, particularly the Th17 subset, with corresponding upregulation of IL-17A both at transcriptional and protein levels. Crucially, we established a mouse model of anti-PD-1-induced sialadenitis and demonstrated that therapeutic blockade of IL-17A restores salivary function. Conclusion: This study establishes ICI-associated sialadenitis as a distinct pathological entity characterized by CD4 + T cell-driven inflammation mediated through the Th17/IL-17 axis, which differs from Sjögren syndrome, predominantly involving B cells and from IgG4 related sialadenitis. By demonstrating therapeutic efficacy in a preclinical model, our findings provide the first preclinical validation of the IL-17 axis as an actionable therapeutic target for this condition.